Herausragende Publikationen
2018
Blood
A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing.
Wehr C, Grotius K, Casadei S, Bleckmann D, Bode SFN, Frye BC, Seidl M, Gulsuner S, King MC, Percival MB, Pritchard CC, Walsh T, Wu D, Keel S, Salzer U.
Blood 2018 Jul 20. pii: blood-2018-03-837336. doi: 10.1182/blood-2018-03-837336.
[Epub ahead of print] No abstract available. PMID: 30030275
Blood
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms
Jan C. Peeken, Jonas S. Jutzi, Julius Wehrle, Christoph Koellerer, Hans F. Staehle, Heiko Becker, Elias Schoenwandt, Thalia S. Seeger, Daniel H. Schanne, Monika Gothwal, Christopher J. Ott, Albert Gründer and Heike L. Pahl
Blood 2018 131:2065-2073; doi: https://doi.org/10.1182/blood-2017-10-810622
Haematologica
Osteoprotective medication in the era of novel agents: European perspective on values, risks and future solutions.
Monika Engelhardt, Georg W. Herget, Giulia Graziani, Gabriele Ihorst, Heike Reinhardt, Stefanie Ajayi, Stefan Knop, and Ralph Wäsch.
Haematologica 2018 [Epub ahead of print]
Science Translational Medicine
Oncogenic JAK2V617F causes PD-L1 expression mediating immune-escape in myeloproliferative neoplasms
Prestipino A, Emhardt A, Aumann K, O´Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi J, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel F, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, Bubnoff N, Pearce EL, Zeiser R.
Science Translational Medicine 10, eaam7729 (2018)| zum Artikel
Pressemitteilung Freiburg, 22.02.2018: ==> Tumorzellen legen Immunsystem lahm
Blood
Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.
Hülsdünker J, Ottmüller, K.J., Neeff H, Koyama M, Gao Z, Thomas, O.S., Follo, M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser M.J., Fife B.T., Blazar, B.R., Beilhack, A, Hill G.R., Häcker G., Zeiser, R.
Blood 2018;10.1182/blood-2017-10-812891. [Epub ahead of print].
Nature Medicine
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.
Nature Medicine. 2018 Feb 12. doi: 10.1038/nm.4484. | zum Artikel
s.a.: ==> Erfolgreiche Kombinations-Therapie bei aggressiver Leukämie (20.02.2018)
Blood
Zeiser R, Sarantopoulos S, Blazar BR.
B-cell targeting in chronic Graft-versus-Host disease.
Blood. 2018 Feb 1. pii: blood-2017-11-784017.
Blood Journal
Introduction to a review series on strategies to improve GVL effects.
Zeiser R.
Blood. 2018 Jan 22. pii: blood-2017-11-814467. doi: 10.1182/blood-2017-11-814467.
Blood Journal
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation
Pfeiffer H, Raum K, Markovic S, Nowak V, Fey S, Obländer J, Pressler J, Böhm V, Brüggemann M, Wunderle L, Hüttmann A, Wäsch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D
Blood, 2018 Jan 18. pii: blood-2017-07-796862. doi: 10.1182/blood-2017-07-796862. | zum Artikel
Nature Communications
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, Nöllke P, Fischer A, Brocks D, Gu Z, Park J, Strahm B, Wlodarski M, Yoshimi A, Claus R, Lübbert M, Busch H, Boerries M, Hartmann M, Schönung M, Kilik U, Langstein J, Wierzbinska JA, Pabst C, Garg S, Catalá A, De Moerloose B, Dworzak M, Hasle H, Locatelli F, Masetti R, Schmugge M, Smith O, Stary J, Ussowicz M, van den Heuvel-Eibrink MM, Assenov Y, Schlesner M, Niemeyer C, Flotho C, Plass C.
Nat Commun. 2017 Dec 19;8(1):2126 | zum Artikel
The New England Journal of Medicine
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.
Zeiser R, Blazar BR. | N Engl J Med. 2017 Dec 28;377(26):2565-2579.
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.
Zeiser R, Blazar BR. | N Engl J Med. 2017 Nov 30;377(22):2167-2179.
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Mogjiborahman S, Rappsilber J, Giuliani C, Troglio F, Rolland Y, Pruneri G, Kreutmair S, Pallavicini I, Zobel M, Cinquanta M, Minucci S, Gomez C, Santos E, Illert AL, Scita G.
Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.267.
www.ncbi.nlm.nih.gov/pubmed/28819285
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial
Jürgen Finke, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Liisa Volin, Dominik Heim, Hartmut Bertz,Olga Grishina, Gerard Socie
Lancet Haematol 2017;4: e293–301
Full text
Comment | Frédéric Baron
Unrelated donor haemopoietic stem-cell transplantation: ATG or not?
MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation.
Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.
Leukemia (9 May 2017) | doi:10.1038/leu.2017.137
High-throughput sequencing for noninvasive disease detection in hematologic malignancies
Florian Scherer, David M. Kurtz, Maximilian Diehn and Ash A. Alizadeh
Blood 2017 :blood-2017-03-735639; doi:
Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.
Harlander S, Schönenberger D, Toussaint NC, Prummer M, Catalano A, Brandt L, Moch H, Wild PJ, Frew IJ.
Nature Medicine. 2017 May 29. doi: 10.1038/nm.4343. [Epub ahead of print]
New Paper by Rouven Hoefflin et al.
- Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
Rouven Hoefflin, Bernd Lahrmann, Gregor Warsow, Daniel Hübschmann, Cathleen Spath, Britta Walter, Xin Chen, Luisa Hofer, Stephan Macher-Goeppinger, Yanis Tolstov, Nina Korzeniewski, Anette Duensing, Carsten Grüllich, Dirk Jäger, Sven Perner, Gita Schönberg, Joanne Nyarangi-Dix, Sanjay Isaac, Gencay Hatiboglu, Dogu Teber et al.
Nature Communications 7, Article number: ncomms11845doi:10.1038/ncomms11845 | Received 21 January 2016 | Accepted 04 May 2016 | Published 13 June 2016
==> http://www.nature.com/articles/ncomms11845
Cover image, Blood, April 14, 2016
Publikation AG Zeiser | April 14, 2016; Blood
The Journal of Experimental Medicine
New Paper by PD Dr. Christine Dierks und Team:
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. ⇒
Klein C, Zwick A, Kissel S, Forster CU, Pfeifer D, Follo M, Illert AL,Decker S, Benkler T, Pahl H, Oostendorp RA, Aumann K, Duyster J,Dierks C.
J Exp Med. 2016 Feb 8;213(2):273-90. doi: 10.1084/jem.20150556. Epub2016 Feb 1.
ASBMT eNews
Ruxolitinib is Potential Corticosteroid-Refractory GVHD Therapy [PDF]
Original Article ↓
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Leukemia (2015) 29, 2062–2068; doi:10.1038/leu.2015.212;
2015
Neues GvHD Behandlungs Konzept aus Freiburg
Prof. Zeiser/Prof. von Bubnoff
